nach oben

International Journal of Clinical Oncology

Erschienen in:

26.10.2019 | Original Article

Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma

verfasst von: Sappaya Suppanuntaroek, Shingo Hatakeyama, Naoki Fujita, Yuka Kubota, Yuichiro Suzuki, Teppei Okamoto, Yuki Tobisawa, Tohru Yoneyama, Hayato Yamamoto, Kazuyuki Mori, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

We investigated the association between the pretreatment quality of life (QOL) and overall survival (OS) in patients with urothelial carcinoma (UC), as the influence of pretreatment QOL on prognosis remains unclear in patients with localized and metastatic UC.

Methods

Between June 2013 and May 2019, we retrospectively investigated 205 patients with UC who received radical cystectomy or nephroureterectomy for non-metastatic UC (M0 group) or systemic chemotherapy for metastatic UC (M1 group). Patients answered the European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (QLQ-C30) before the treatments. Patients were stratified into two groups: QOL high and low according to the optimal cutoff scores which were defined by receiver operating characteristic curve. Inverse probability of treatment weighting (IPTW)-adjusted multivariate Cox regression analyses were performed to investigate the clinical implication of pretreatment QOL score on OS in patients with UC.

Results

The number of patients in the M0 and M1 groups was 125 and 80, respectively. Optimal cutoff values in global, fatigue, pain, appetite loss, physical, and role scores were < 50, > 33, > 33, > 16, < 80, and < 67, respectively. IPTW-adjusted multivariate Cox regression analyses revealed that appetite loss score indicated a significantly poorer OS in the M1 group. No significant association of QOL with OS was observed in the M0 group.

Conclusion

Pretreatment QOL of appetite loss may predict poor prognosis of patients with metastatic UC.

Quinten C, Coens C, Mauer M et al (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10(9):865–871CrossRef

Di Maio M, Basch E, Bryce J et al (2016) Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 13(5):319–325CrossRef

Adeloye D, Harhay MO, Ayepola OO et al (2019) Estimate of the incidence of bladder cancer in Africa: a systematic review and Bayesian meta-analysis. Int J Urol 26(1):102–112CrossRef

Iwamura H, Hatakeyama S, Sato M et al (2018) Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma. Med Oncol 35(6):94CrossRef

Momota M, Hatakeyama S, Tokui N et al (2018) The impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with urothelial carcinoma. Eur Urol Focus. https://doi.org/10.1016/j.euf.2018.03.003 CrossRefPubMed

Kusaka A, Hatakeyama S, Hosogoe S et al (2017) Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer. Med Oncol 34(5):90CrossRef

Nakayama T, Kitano S (2019) Immunotherapy for genitourinary tumors. Int J Urol 26(3):326–333CrossRef

Shao IH, Chang YH, Pang ST (2019) Recent advances in upper tract urothelial carcinomas: from bench to clinics. Int J Urol 26(2):148–159CrossRef

Okita K, Hatakeyama S, Fujita N et al (2018) Postoperative weight loss followed by radical cystectomy predicts poor prognosis in patients with muscle-invasive bladder cancer. Med Oncol 36(1):7CrossRef

10.

Inamoto T, Ibuki N, Komura K et al (2018) Can bladder preservation therapy come to the center stage? Int J Urol 25(2):134–140CrossRef

11.

Tan YG, Eu EWC, Huang HH et al (2018) High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer. Int J Urol 25(3):232–238CrossRef

12.

Nakayama M, Ito Y, Hatano K et al (2019) Impact of sex difference on survival of bladder cancer: a population-based registry data in Japan. Int J Urol 26(6):649–654CrossRef

13.

Powles T, Necchi A, Rosen G et al (2018) Anti-Programmed cell death 1/ligand 1 (PD-1/PD-L1) antibodies for the treatment of urothelial carcinoma: state of the art and future development. Clin Genitourin Cancer 16(2):117–129CrossRef

14.

Fukushi K, Narita T, Hatakeyama S et al (2017) Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma. Int J Clin Oncol 22(2):366–372CrossRef

15.

Fukushi K, Narita T, Hatakeyama S et al (2017) Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma. Int J Urol 24(5):361–366CrossRef

16.

Royce TJ, Feldman AS, Mossanen M et al (2019) Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer. Clin Genitourin Cancer 17(1):23–31.e23CrossRef

17.

Roychowdhury DF, Hayden A, Liepa AM (2009) Rural Income Generating Activities: Whatever Happened to the Institutional Vacuum? Evidence from Ghana, Guatemala, Nicaragua and Vietnam. World Development 37(7):1297CrossRef

18.

Meier A, Yopp A, Mok H et al (2015) Role functioning is associated with survival in patients with hepatocellular carcinoma. Qual Life Res 24(7):1669–1675CrossRef

19.

Taarnhoj GA, Johansen C, Pappot H (2019) Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature. Health Qual Life Outcomes 17(1):20CrossRef

20.

Anan G, Hatakeyama S, Fujita N et al (2017) Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study. Oncotarget 8(49):86130–86142CrossRef

21.

Hosogoe S, Hatakeyama S, Kusaka A et al (2017) Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 4(6):946–953. https://doi.org/10.1016/j.euf.2017.03.013 CrossRefPubMed

22.

De Santis M, Bellmunt J, Mead G et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30(2):191–199CrossRef

23.

Koie T, Ohyama C, Makiyama K et al (2019) Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer. Int J Urol 26(3):334–340CrossRef

24.

Kido K, Hatakeyama S, Fujita N et al (2018) Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma. Int J Clin Oncol 23(4):726–733CrossRef

25.

Kobayashi K, Takeda F, Teramukai S et al (1998) A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer. Eur J Cancer 34(6):810–815CrossRef

26.

Tóth G, Tsukuda M (2010) The Japanese Version of the EORTC Quality of Life Questionnaire. In: Preedy VR, Watson RR (eds) Handbook of disease burdens and quality of life measures. Springer New York, pp 285–309. doi: 10.1007/978-0-387-78665-0_16CrossRef

27.

Brajša-Žganec A, Merkaš M, Šverko I (2010) Quality of life and leisure activities: how do leisure activities contribute to subjective well-being? Soc Indic Res 102(1):81–91CrossRef

28.

Tomioka K, Kurumatani N, Hosoi H (2016) Relationship of having hobbies and a purpose in life with mortality, activities of daily living, and instrumental activities of daily living among community-dwelling elderly adults. J Epidemiol 26(7):361–370CrossRef

29.

Movsas B, Moughan J, Sarna L et al (2009) Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 27(34):5816–5822CrossRef

30.

Snyder CF, Blackford AL, Okuyama T et al (2013) Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Qual Life Res 22(10):2685–2691CrossRef

31.

Jansen F, Snyder CF, Leemans CR et al (2016) Identifying cutoff scores for the EORTC QLQ-C30 and the head and neck cancer-specific module EORTC QLQ-H&N35 representing unmet supportive care needs in patients with head and neck cancer. Head Neck 38(Suppl 1):E1493–1500CrossRef

Titel: Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma
verfasst von: Sappaya Suppanuntaroek
Shingo Hatakeyama
Naoki Fujita
Yuka Kubota
Yuichiro Suzuki
Teppei Okamoto
Yuki Tobisawa
Tohru Yoneyama
Hayato Yamamoto
Kazuyuki Mori
Atsushi Imai
Takahiro Yoneyama
Yasuhiro Hashimoto
Chikara Ohyama
Publikationsdatum: 26.10.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01563-2

Springer Medizin

Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma